Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at Hunan Warrant PharmaceuticalLtd's (SHSE:688799) recent performance, when its stock has declined 21% over the past three months. However, stock prices are usually driven by a company's financial performance over the long term, which in this case looks quite promising. Particularly, we will be paying attention to Hunan Warrant PharmaceuticalLtd's ROE today.
湖南万瑞特药业股份有限公司(SHSE:688799)最近的表现并不令人兴奋,过去三个月股价下跌了21%。但通常情况下,股价由公司长期的财务表现所驱动,在这种情况下,公司表现非常有前途。特别是,我们将关注湖南万瑞特药业股份有限公司的roe。
Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
股东要考虑的关键因素之一是净资产收益率或roe,因为它告诉他们公司如何有效地重新投资他们的资本。简单点说,它衡量了公司与股东权益相关的盈利能力。
How To Calculate Return On Equity?
如何计算股东权益报酬率?
Return on equity can be calculated by using the formula:
股东权益报酬率可以使用以下公式计算:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
净资产收益率 = 净利润(从持续经营中获得)÷ 股东权益
So, based on the above formula, the ROE for Hunan Warrant PharmaceuticalLtd is:
所以,根据上述公式,湖南万瑞特药业股份有限公司的roe为:
11% = CN¥201m ÷ CN¥1.8b (Based on the trailing twelve months to March 2024).
11% = CN¥20100万 ÷ CN¥18亿(基于截至2024年3月的过去十二个月)。
The 'return' is the amount earned after tax over the last twelve months. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.11 in profit.
“回报”是指公司过去十二个月税后所赚的金额。这意味着,每1元股东权益产生了0.11元的利润。
What Is The Relationship Between ROE And Earnings Growth?
既然我们已经确定ROE是一种有效的利润生成标准,用于评估公司未来的盈利能力,我们现在需要评估公司“保留”为未来增长而重新投资的利润多少,这使我们对公司的增长潜力有了一个了解。一般而言,在其他条件相等的情况下,ROE和利润留存高的公司,增长率比没有这些属性的公司要高。
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
我们已经确定,roe是一个有效的利润生成衡量标准,用于评估公司未来的盈利能力。根据公司再投资或“保留”这些利润的比例以及这样做的有效性,我们能够评估公司的盈利增长潜力。假设其他所有因素保持不变,roe和利润保留的比例越高,相对于没有这些特征的公司,公司的增长率就越高。
Hunan Warrant PharmaceuticalLtd's Earnings Growth And 11% ROE
湖南万瑞特药业股份有限公司的盈利增长与11%良好roe。
To start with, Hunan Warrant PharmaceuticalLtd's ROE looks acceptable. On comparing with the average industry ROE of 7.6% the company's ROE looks pretty remarkable. This probably laid the ground for Hunan Warrant PharmaceuticalLtd's moderate 14% net income growth seen over the past five years.
首先,湖南万瑞特药业股份有限公司的roe看起来比较可接受。与7.6%的行业平均roe相比,该公司的roe相当引人注目。这可能为湖南万瑞特药业股份有限公司在过去五年中实现的适度净利润增长(14%)奠定了基础。
We then compared Hunan Warrant PharmaceuticalLtd's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 9.2% in the same 5-year period.
然后,我们将湖南万瑞特药业股份有限公司的净利润增长与整个行业进行了比较,很高兴看到该公司的增长率在同期的五年中要高于行业的增长率,后者为9.2%。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240726/0-850547ff9fe675558de58b46c38a6ab8-0-87fc73fd3ed39f6809e13276bc35f04b.png/big)
Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Hunan Warrant PharmaceuticalLtd is trading on a high P/E or a low P/E, relative to its industry.
盈利增长是考虑股票估值时很重要的指标。了解市场是否已经定价公司预期的盈利增长(或下降)对于投资者来说非常重要。这有助于他们判断股票未来是否光明或黯淡。一个衡量预期盈利增长的好指标是市盈率(P/E比),该比率根据公司的盈利前景确定市场愿意为一支股票支付的价格。因此,您可能需要查看湖南万瑞特药业股份有限公司是否相对于其行业在高或低市盈率下进行交易。
Is Hunan Warrant PharmaceuticalLtd Efficiently Re-investing Its Profits?
湖南万瑞特药业股份有限公司是否有效地再利用了其利润?
With a three-year median payout ratio of 38% (implying that the company retains 62% of its profits), it seems that Hunan Warrant PharmaceuticalLtd is reinvesting efficiently in a way that it sees respectable amount growth in its earnings and pays a dividend that's well covered.
通过三年的中位数支付比率(表明公司保留了其利润的62%),看起来湖南万瑞特药业股份有限公司正在有效地重新投资,以实现可观的盈利增长并支付股息。
While Hunan Warrant PharmaceuticalLtd has been growing its earnings, it only recently started to pay dividends which likely means that the company decided to impress new and existing shareholders with a dividend.
虽然湖南万瑞特药业股份有限公司一直在增长其盈利,但只是最近开始支付股息,这可能意味着该公司决定通过派送股息来吸引新老股东。
Summary
总的来说,我们对伟明环保的表现非常满意。具体而言,我们喜欢公司以高回报率再投资了其利润的很大一部分。当然,这导致公司的收益大幅增长。但是,最新的行业分析师预测表明,该公司的收益预计将加速增长。
On the whole, we feel that Hunan Warrant PharmaceuticalLtd's performance has been quite good. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Remember, the price of a stock is also dependent on the perceived risk. Therefore investors must keep themselves informed about the risks involved before investing in any company. You can see the 1 risk we have identified for Hunan Warrant PharmaceuticalLtd by visiting our risks dashboard for free on our platform here.
总体而言,我们认为湖南万瑞特药业股份有限公司的表现相当不错。特别是,看到该公司大量投资于其业务,并伴随着高回报率,这导致其盈利显著增长,这是非常棒的。如果该公司继续像现在这样增长其盈利,那将对其股价产生积极的影响,因为每股收益如何影响长期股价。记住,一支股票的价格还取决于其被认为的风险。因此,在投资任何公司之前,投资者必须了解相关的风险。您可以在我们的平台上免费查看我们为湖南万瑞特药业股份有限公司确定的风险仪表板。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。